CTRI/2014/02/004391
Completed
未知
A randomized, double blind, balanced, single center, two treatment, two period, two sequence, single dose, crossover relative bioavailability study of turmeric extracts in healthy human adult subjects, under fasting conditions.
Exodus Research Acer0 sites16 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Exodus Research Acer
- Enrollment
- 16
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •a.Be healthy male or non\-pregnant and non\-lactating female 18 to 45 years of age, both ages inclusive.
- •b.Be healthy male or non\-pregnant and non\-lactating female of BMI within 18\.50 to 24\.99 Kg/ m2\. Volunteers weighing less than 50 kg will not be enrolled.
- •c.Be able to communicate effectively with the study personnel.
- •d.Be a non consumer (user) of tobacco (not consumed tobacco in the past 6 months) or a mild or moderate consumer (user) of tobacco.
- •e.Have no evidence of underlying disease during screening medical history and whose physical examination is performed within 21 days prior to check in of period one.
- •f.Be medically healthy with clinically acceptable laboratory profiles, ECG (performed within 21 days prior to check\-in of period one) and chest X\-ray (performed within 6 months prior to check\-in of period one).
- •g.Have given the written informed consent for voluntary participation in the study.
- •h.Be declared eligible to participate in the study by the investigator(s).
- •i.In addition, female volunteers selected for the study must:
- •i)Be using a medically acceptable form of birth control (such as foams, jellies, diaphragm, intra\-uterine device (IUD) or abstinence) for the duration of the study as judged by the investigator(s) Or
Exclusion Criteria
- •a.Participation in any bioavailability, bioequivalence, Pharmacokinetic study or received an investigational drug within a period of 3 months prior to check in of period one.
- •b.History of drug abuse, or alcohol dependence or abuse.
- •c.History of any allergies (asthma, urticaria) including drug allergies.
- •d.Known hypersensitivity or allergy to curcuminoids or any of the excipients or related drugs
- •e.Severe consumer of tobacco.
- •f.Presence of a clinically significant disorder involving the cardiovascular,respiratory, renal, gastrointestinal, hepatic, immunologic, hematological, endocrine, or nervous system or psychiatric disease or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk, as determined by the investigator.
- •g.Volunteers who have,
- •i.Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg. Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg. Minor deviations 2\-4 mm of Hg at check\-in may be acceptable at the discretion of the physician /investigator.
- •ii.Pulse rate below 60 per minute or above 100 per minute.
- •iii.Respiratory rate below 15 or above 20 breaths per minute.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
This study is designed to evaluate and compare the ease of swallowing and palatability (roughness, stickiness, slipperiness, and taste), of specialized coating(easyglide) vs conventional (Opadry) coating and uncoated placebo tablets in healthy adult volunteers.CTRI/2020/11/029406Abbott Healthcare Pvt Ltd
Completed
Phase 3
To evaluate effect of KSM-66 Ashwagandha® Capsule (300 mg) in Management of Frailty in Older AdultsCTRI/2022/02/040554Ixoreal Biomed50
Active, not recruiting
Phase 1
A clinical trial testing usual dose and double dose oseltamivir (the medicine) in which neither the doctor or patient know what dose of medicine is given for treatment of influenza (the flu), in patients with a weakened immune (protective) system.To investigate the optimal therapy for influenza in immunocompromised patients.MedDRA version: 17.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2006-002468-24-HUF.Hoffmann-La Roche Ltd.166
Active, not recruiting
Phase 1
A clinical trial testing usual dose and double dose oseltamivir (the medicine) in which neither the doctor or patient know what dose of medicine is given for treatment of influenza (the flu), in patients with a weakened immune (protective) system.EUCTR2006-002468-24-BGF.Hoffmann-La Roche Ltd.228
Active, not recruiting
Phase 1
A clinical trial testing usual dose and double dose oseltamivir (the medicine) in which neither the doctor or patient know what dose of medicine is given for treatment of influenza (the flu), in patients with a weakened immune (protective) system.To investigate the optimal therapy for influenza in immunocompromised patients.MedDRA version: 19.1 Level: PT Classification code 10022000 Term: Influenza System Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2006-002468-24-DEF.Hoffmann-La Roche Ltd.215